1. Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y, Morais C, Kumar S, Sklar P, Hanna GJ, Hwang C, Greaves W, DRIVE-SHIFT Study Group. 2019. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr 81:463–472.

2. Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai M-T. 2015. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 59:590–598.

3. Brenner BG, Oliveira M, Ibanescu R-I, Routy J-P, Thomas R. 2021. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir. Journal of Antimicrobial Chemotherapy https://doi.org/10.1093/jac/dkab126.

4. Orkin C, Squires KE, Molina J-M, Sax PE, Wong W-W, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen B-Y, Hanna GJ, Hwang C, Martin EA, DRIVE-AHEAD Study Group. 2019. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis 68:535–544.

5. Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. 2021. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clinical Infectious Diseases 73:33–42.

6. Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai M-T, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA, DRIVE-FORWARD trial group. 2020. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV 7:e16–e26.

7. Lai M-T, Feng M, Falgueyret J-P, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau L-C, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD. 2014. In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrobial Agents and Chemotherapy 58:1652–1663.

8. Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, Miller MD, Lai M-T. 2016. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrobial Agents and Chemotherapy 60:2241–2247.

9. Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH. 2016. Rilpivirine and Doravirine have complementary efficacies against NNRTI-Resistant HIV-1 mutants: JAIDS Journal of Acquired Immune Deficiency Syndromes 1.

10. Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccuto A, Dragoni F, Vicenti I, Shafer RW, Zazzi M. 2021. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. Journal of Antimicrobial Chemotherapy 76:130–134.

11. Asante-Appiah E, Lai J, Wan H, Yang D, Martin EA, Sklar P, Hazuda D, Petropoulos CJ, Walworth C, Grobler JA. 2021. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates. Antimicrobial Agents and Chemotherapy https://doi.org/10.1128/AAC.01216-21.

12. Hazuda D, Xu M, Ngo W, Feng M, Hwang C, Grobler J, Lai M-T. 2018. Understanding the resistance profile of the HIV-1 NNRTI doravirine in combination with the novel NNRTI MK-8591 [Abstract THPEB068]. , Amsterdam, July 23-27, 2018 www.AIDS2018.org.

13. Lai M-T, Xu M, Ngo W, Feng M, Hazuda D, Hanna G, Kumar S, Xu X, Martin E, Hwang C. 2018. Characterization of doravirine-selected resistance patterns from participants in treatment-naive phase 3 clinical trials.